The antibody-drug conjugate Datroway (datopotamab deruxtecan), in combination with the bispecific antibody rilvegostomig, shows high objective response rates and disease control exceeding 95% in patients with advanced urothelial carcinoma, including those ineligible for cisplatin-based chemotherapy. The findings come from the Phase 2 TROPION-PanTumor03 trial and have prompted initiation of the pivotal Phase 2/3 TROPION-Urothelial03 study.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
